Are Oxygenta Pharma latest results good or bad?

Oxygenta Pharmaceutical's financial results for the quarter ending June 2025 present a mixed picture. The company reported net sales of Rs 64.60 crore, which indicates a substantial year-on-year growth of 178.81%, suggesting strong demand for its products over the last six months. However, this positive sales performance is contrasted by significant losses. The profit before tax less other income (PBT) for the quarter is reported at Rs -8.31 crore, reflecting a notable decline of 192.61% year-on-year. Similarly, the profit after tax (PAT) has fallen to Rs -6.10 crore, with a staggering decrease of 348.5% compared to the previous year.
The operating profit has also reached its lowest point in five quarters at Rs -6.83 crore, resulting in an operating profit margin of -45.14%, which indicates a decline in the company's operational efficiency. Furthermore, earnings per share (EPS) have dropped to Rs -1.65, highlighting a reduction in profitability and lower returns for shareholders.

Additionally, the company saw an adjustment in its evaluation, reflecting the challenges faced in the current financial landscape. Overall, while Oxygenta Pharma has demonstrated strong sales growth, the substantial losses and declining profitability metrics suggest underlying operational difficulties that need to be addressed.